TY - JOUR
T1 - Immunological basis for treatment of graft versus host disease after liver transplant
AU - Rai, Vikrant
AU - Dietz, Nicholas Edward
AU - Agrawal, Devendra K.
PY - 2016/5/3
Y1 - 2016/5/3
N2 - Graft versus host disease (GVHD) after liver transplant, although a rare disease, has a very high mortality rate. GVHD occurs due to immunoreactions caused by donor T lymphocytes and host cell surface antigens resulting in proliferation and clonal expansion of T lymphocyte. Migration of effector cells, including macrophages, NK cells and cytotoxic T lymphocyte, to the target organs such as skin, intestine and bone marrow results in skin rashes, diarrhea and bone marrow depression. GVHD is diagnosed by clinical symptoms, histopathological findings and by the presence of chimerism. The delayed diagnosis, opportunistic infections and lack of definitive treatment of post orthotopic liver transplant (OLT)-GVHD results in sepsis and multi-organ failure leading to very low survival rates. In this review, we have focused on early diagnosis and critically discuss novel treatment modalities to decrease the incidence of GVHD.
AB - Graft versus host disease (GVHD) after liver transplant, although a rare disease, has a very high mortality rate. GVHD occurs due to immunoreactions caused by donor T lymphocytes and host cell surface antigens resulting in proliferation and clonal expansion of T lymphocyte. Migration of effector cells, including macrophages, NK cells and cytotoxic T lymphocyte, to the target organs such as skin, intestine and bone marrow results in skin rashes, diarrhea and bone marrow depression. GVHD is diagnosed by clinical symptoms, histopathological findings and by the presence of chimerism. The delayed diagnosis, opportunistic infections and lack of definitive treatment of post orthotopic liver transplant (OLT)-GVHD results in sepsis and multi-organ failure leading to very low survival rates. In this review, we have focused on early diagnosis and critically discuss novel treatment modalities to decrease the incidence of GVHD.
UR - http://www.scopus.com/inward/record.url?scp=84959055395&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959055395&partnerID=8YFLogxK
U2 - 10.1586/1744666X.2016.1145056
DO - 10.1586/1744666X.2016.1145056
M3 - Review article
C2 - 26795873
AN - SCOPUS:84959055395
SN - 1744-666X
VL - 12
SP - 583
EP - 593
JO - Expert Review of Clinical Immunology
JF - Expert Review of Clinical Immunology
IS - 5
ER -